Several clinical studies have revealed high heterogeneity of expression and low efficiency of the PCA3 biomarker in detection of high-risk tumors, questioning its robustness and reliability in PCa diagnostics (Alshalalfa et al, 2017; Fenstermaker et al, 2017). Here, PCA3 is linked to posterior cortical atrophy.